Atopic Dermatitis Drugs Market Size, Share & Trends Analysis Report By Drug Class (Corticosteroids, Calcineurin Inhibitors, PDE4 Inhibitors, Biologics), By RoA, And Segment Forecasts, 2016 - 2022

Published: Aug, 2018 | Pages: 84 | Publisher: Grand View Research
Industry: Pharmaceutical | Report Format: Electronic (PDF)

The global atopic dermatitis drugs market size is expected to reach USD 6.41 billion by 2022, according to a new report by Grand View Research, Inc., exhibiting a CAGR of 6.6% during the forecast period. Various factors such as emergence of novel therapeutics and growing uptake of targeted therapies are stimulating the growth of the market.

Eucrisa (Pfizer; crisaborole ointment) was approved by the U.S. FDA for treatment of atopic dermatitis (AD), in 2016. The drug is indicated for mild-to-moderate AD in patients who are two years or older, meeting a key therapeutics need of the market. Dupixent (Sanofi/Regeneron) was the first biologic to be launched in 2017 for management of AD. The drug is under clinical investigation for use in pediatric population.

Several promising candidates, especially biologics and small molecules, in pipeline are expected to alter the AD therapeutic landscape post launch. Nemolizumab is anticipated to be the first biologic (anti-IL-13) indicated for itching associated with atopic dermatitis. Tralokinumab, an IL-13 inhibitor, is under evaluation for safety and efficacy of treatment of moderate-to-severe AD.

Upcoming patent expiration of key products, such as LEO Pharma's Protopic, Mylan/Valeant's Elidel, and Bayer's Desonate will result in generic penetration in therapeutic space. However, novel therapeutics, such as Eucrisa and Dupixent, are likely to gain traction over the forecast period and attain blockbuster status.

Underdeveloped and unserved categories such as rarer subtypes and pediatric population offer strong commercial opportunities. Drug companies are currently investigating multiple treatment options in niche indications such as severe refractory atopic dermatitis. Improving availability of new treatment modalities and targeted approaches offer a promising future for the global atopic dermatitis drugs market.

Further key findings from the report suggest:

• Corticosteroids dominated the drug class in 2016, owing to their indication as first-line therapeutics for atopic dermatitis

• Recent launch of biologics and small molecules such as Dupixent and Eucrisais likely to change the current therapeutic scenario due to their target-oriented mechanism of action

• Calcineurin inhibitors are likely to witness stifled growth because of adverse effects, non-specificity, and development of resistance to chemical agents

• The U.S. was the leading regional market in 2016. It is posed to maintain its position through 2022, owing to burgeoning disease burden, increasing treatment rate, and high drug cost

• The topical segment led the atopic dermatitis drugs market in 2016, based on route of administration. Although the segment is expected to continue leading the market through 2022, Dupixent's launch in 2017 marked the arrival of injectable. The new RoA is anticipated to hold approximately 30.0% market share by 2022

• Bayer, LEO Pharma, Mylan, Pfizer, and Sanofi are some of key players operating in the market

• Pfizer and Sanofi are anticipated to be leaders in AD therapeutic space by 2022 due to growing adoption of targeted therapies, such as Eucrisa and Dupixent

• Rarer subtypes, such as severe refractory atopic dermatitis, have few treatment options available and lack a significant pipeline. This field presents a strong commercial opportunity to drug developers.

 Table of Contents

Chapter 1 Research Methodology
                 1.1 Information Procurement
                 1.2 Information or Data Analysis
                     1.2.1 Market Formulation & Validation
Chapter 2 Executive Summary
Chapter 3 Disease Primer and Epidemiology
                 3.1 Disease Primer
                     3.1.1 Symptoms
                     3.1.2 Risk Factors
                     3.1.3 Complications
                 3.2 Epidemiology by Indications
                 3.3 Current Prevalence for Seven Major Markets (U.S., Japan, EU5)
                 3.4 Current Incidence for Seven Major Markets (U.S., Japan, EU5)
                 3.5 Forecast Prevalence and Incidence for Seven Major Markets (U.S., Japan, EU5)
Chapter 4 Global Atopic Dermatitis Drugs Market Overview
                 4.1 Introduction and Market Overview
                     4.1.1 Segmentation, by Mode of Administration
                         4.1.1.1 Topical
                         4.1.1.2 Injectable
                         4.1.1.3 Oral
                     4.1.2 Segmentation, by Drug Class
                         4.1.2.1 Corticosteroids
                         4.1.2.2 Calcineurin Inhibitors
                         4.1.2.3 PDE4 Inhibitors
                         4.1.2.4 Biologics
                         4.1.2.5 Others
                     4.1.3 Market Size and Forecast
                     4.1.4 Sales Performance
                     4.1.5 Market Share Distribution
                     4.1.6 Market Dynamics among Leading Brands
                 4.2 Patent Expiry Schedule
                 4.3 Drivers and Challenges
                 4.4 M&A, Deal Landscape (YTD 2013-2018)
                 4.5 Pricing and Reimbursement
                 4.6 SWOT Analysis
Chapter 5 Atopic Dermatitis Drugs Market: Pipeline Intelligence
                 5.1 Pipeline Landscape
                     5.1.1 Drugs in Development
                     5.1.2 Key R&D Trends
                         5.1.2.1 PDE4 inhibitor
                         5.1.2.2 JAK inhibitor
                         5.1.2.3 Biologics
                 5.2 Promising Drugs
                     5.2.1 Late-Stage Pipeline
                     5.2.2 Profile of Disruptive Drugs
                         5.2.2.1 Tralokinumab
                         5.2.2.2 PF-04965842
                         5.2.2.3 Dupixent
Chapter 6 Company Profiles
                 6.1 Bayer
                     6.1.1 Company Overview
                     6.1.2 Current Product Portfolio
                     6.1.3 Company - Key News Flow
                     6.1.4 Catalysts and Event Calendar
                     6.1.5 SWOT Analysis
                 6.2 LEO Pharma
                     6.2.1 Company Overview
                     6.2.2 Current Product Portfolio
                     6.2.3 Product Forecast Sales up to 2022
                     6.2.4 Company - Key News Flow
                     6.2.5 Pipeline View
                     6.2.6 Pipeline Forecast
                     6.2.7 Catalysts and Event Calendar
                     6.2.8 SWOT Analysis
                 6.3 Mylan
                     6.3.1 Company Overview
                     6.3.2 Current Product Portfolio
                     6.3.3 Product Forecast Sales up to 2022
                     6.3.4 Company - Key News Flow
                     6.3.5 Catalysts and Event Calendar
                     6.3.6 SWOT Analysis
                 6.4 Pfizer
                     6.4.1 Company Overview
                     6.4.2 Current Product Portfolio
                     6.4.3 Product Forecast Sales up to 2022
                     6.4.4 Company - Key News Flow
                     6.4.5 Pipeline View
                     6.4.6 Pipeline Forecast
                     6.4.7 Catalysts and Event Calendar
                     6.4.8 SWOT Analysis
                 6.5 Sanofi
                     6.5.1 Company Overview
                     6.5.2 Current Product Portfolio
                     6.5.3 Product Forecast Sales up to 2022
                     6.5.4 Company - Key News Flow
                     6.5.5 Pipeline View
                     6.5.6 Pipeline Forecast
                     6.5.7 Catalysts and Event Calendar
                     6.5.8 SWOT Analysis
Chapter 7 Market Outlook
                 7.1 What the Future Holds
                 7.2 Winners and Losers
                 7.3 Emerging Companies
                 7.4 The Road Ahead

List of Tables

TABLE 1 Current Atopic Dermatitis Prevalence Across Seven Major Markets - 2016
TABLE 2 Current Atopic Dermatitis Incidence Across Seven Major Markets - 2016
TABLE 3 Forecast Atopic Dermatitis Prevalence Across Seven Major Markets, 2016 - 2022
TABLE 4 Forecast Atopic Dermatitis Incidence Across Seven Major Markets, 2016 - 2022
TABLE 5 Atopic Dermatitis Drugs Market Size and Forecast (in USD million)
TABLE 6 Geographic Sales Performance, by Seven Major Markets (in $million)
TABLE 7 Atopic Dermatitis Drugs Market, by Drug Class (in $million)
TABLE 8 Atopic Dermatitis Drugs Market, by Route of Administration (in $million)
TABLE 9 Forecast Sales of Leading Brands (in $million)
TABLE 10 Global Atopic Dermatitis Cancer Drugs Pipeline Forecast
TABLE 11 Atopic Dermatitis Drugs Sales Forecast, by Company (in $million)
TABLE 12 Atopic Dermatitis Drugs Market Share, by Company (in $million)
TABLE 13 Atopic Dermatitis Drugs Market: Patent Expiry Schedule
TABLE 14 Atopic Dermatitis Deal Landscape YTD (2013 - 2018)
TABLE 15 Atopic Dermatitis Drugs in Development
TABLE 16 Late-Stage Atopic Dermatitis Pipeline
TABLE 17 Profile of Disruptive Drug: Tralokinumab
TABLE 18 Profile of Disruptive Drug: PF-04965842
TABLE 19 Profile of Disruptive Drug: Dupixent
TABLE 20 Product Portfolio: Desonate
TABLE 21 Bayer Catalysts and Event Calendar
TABLE 22 Product Portfolio: Protopic
TABLE 23 Protopic Sales Forecast Through 2022
TABLE 24 LEO Pharma Pipeline View
TABLE 25 LEO Pharma Catalysts and Event Calendar
TABLE 26 Product Portfolio: Elidel
TABLE 27 Elidel Sales Forecast Through 2022
TABLE 28 Mylan Catalysts and Event Calendar
TABLE 29 Product Portfolio: Eucrisa
TABLE 30 Eucrisa Sales Forecast through 2022
TABLE 31 Pfizer Pipeline View
TABLE 32 Bayer Catalysts and Event Calendar
TABLE 33 Product Portfolio: Dupixent
TABLE 34 Dupixent Sales Forecast Through 2022
TABLE 35 Sanofi Pipeline View
TABLE 36 Bayer Catalysts and Event Calendar

List of Figures

FIG. 1 Market Research Process
FIG. 2 Information Procurement
FIG. 3 Primary Research Pattern
FIG. 4 Market Research Approaches
FIG. 5 Value Chain Based Sizing & Forecasting
FIG. 6 QFD Modelling for Market Share Assessment
FIG. 7 Atopic Dermatitis Prevalence Across Seven Major Markets - 2016
FIG. 8 Atopic Dermatitis Incidence Across Seven Major Markets - 2016
FIG. 9 Market Segmentation & Scope
FIG. 10 Geographic Sales Performance, by Seven Major Markets 2016
FIG. 11 Atopic Dermatitis Drugs Market, Sales by Drug Class (in $million)
FIG. 12 Atopic Dermatitis Trend, by Drug Class
FIG. 13 Atopic Dermatitis Drugs Market, Sales by Route of Administration (in $million)
FIG. 14 U.S. Atopic Dermatitis Drugs Market Shares, by Drug Class (2016A - 2022E)
FIG. 15 U.K. Atopic Dermatitis Drugs Market Shares, by Drug Class (2016A - 2022E)
FIG. 16 Germany Atopic Dermatitis Drugs Market Shares, by Drug Class (2016A - 2022E)
FIG. 17 Spain Atopic Dermatitis Drugs Market Shares, by Drug Class (2016A - 2022E)
FIG. 18 Italy Atopic Dermatitis Drugs Market Shares, by Drug Class (2016A - 2022E)
FIG. 19 France Atopic Dermatitis Drugs Market Shares, by Drug Class (2016A - 2022E)
FIG. 20 Japan Atopic Dermatitis Drugs Market Shares, by Drug Class (2016A - 2022E)
FIG. 21 U.S. Atopic Dermatitis Drugs Market, Sales by Route of Administration (in $million)
FIG. 22 U.K. Atopic Dermatitis Drugs Market, Sales by Route of Administration (in $million)
FIG. 23 Germany Atopic Dermatitis Drugs Market, Sales by Route of Administration (in $million)
FIG. 24 Spain Atopic Dermatitis Drugs Market, Sales by Route of Administration (in $million)
FIG. 25 Italy Atopic Dermatitis Drugs Market, Sales by Route of Administration (in $million)
FIG. 26 France Atopic Dermatitis Drugs Market, Sales by Route of Administration (in $million)
FIG. 27 Japan Atopic Dermatitis Drugs Market, Sales by Route of Administration (in $million)
FIG. 28 Atopic Dermatitis Drugs Market Share, by Company (2016A - 2022E)
FIG. 29 Market Trends & Outlook
FIG. 30 Market Driver Relevance Analysis (Current & Future Impact)
FIG. 31 Market Restraint Relevance Analysis (Current & Future Impact)
FIG. 32 SWOT Analysis (Atopic Dermatitis Drugs Market)
FIG. 33 Pipeline Assets by Phase
FIG. 34 SWOT Analysis (Bayer)
FIG. 35 SWOT Analysis (LEO Pharma)
FIG. 36 SWOT Analysis (Mylan)
FIG. 37 SWOT Analysis (Pfizer)
FIG. 38 SWOT Analysis (Sanofi)